Toripalimab
拓益(Loqtorzi)
The first China-developed PD-1 immunotherapy; later became the first Chinese PD-1 approved by the US FDA.
At a glance
China price
Verified pricing is not currently available.
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
Source(s)
- https://www.himd.com/toripalimab/22236839
Secondary source (media / community / commercial)
NRDL (national insurance)
In NRDL.
Regulatory status
NMPA approved; NRDL 2023
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
SourceNo independent source on file.
NotesApproval status from public regulatory reporting.
What it treats
Melanoma, nasopharyngeal carcinoma, urothelial and other cancers.
2026(himd.com)
Sources & verification
- https://www.himd.com/toripalimab/22236839 — Secondary source (media / community / commercial)
Reader discussion
Public comments about Toripalimab. Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.